Tolerance Bio Licenses IL-7 Drug in Deal Worth Up to $260 Million
PHILADELPHIA, PA — Tolerance Bio Inc. licensed regional rights to NeoImmuneTech’s clinical-stage immune therapy efineptakin alfa in a deal carrying as much as $260 million in potential milestone payments, moving …
Tolerance Bio Licenses IL-7 Drug in Deal Worth Up to $260 Million Read More